Inscripta Inc., a company developing a full suite of gene editing tools that it hopes will democratize access to CRISPR-based research and development, has landed a $55.5 million series C funding that it said will help accelerate the development and commercialization of its platform. The financing follows a $23 million series B round in February 2017 and a $6 million series A round in February 2016.